Donadon Matteo, Costa Guido, Cimino Matteo, Procopio Fabio, Fabbro Daniele Del, Palmisano Angela, Torzilli Guido
Department of Hepatobiliary Surgery, Humanitas Research Hospital, University of Milan School of Medicine, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
World J Surg. 2015 Jan;39(1):237-43. doi: 10.1007/s00268-014-2786-6.
Selection criteria for hepatectomy for hepatocellular carcinoma (HCC) are object of debate. We presented our criteria for safe hepatectomy for HCC, and we compared the results with those obtainable using the most common scores for HCC.
All patients submitted to hepatectomy for HCC based on the same criteria were reviewed from our prospectively maintained database. Such criteria included bilirubin (BIL), cholinesterases (CHE), ascites, esophageal varices, and residual liver volume.
A total of 336 patients were analyzed. One hundred fifteen patients (33 %) had thoracoabdominal approach, but only 39 (12 %) had major or extended resections. The median tumor number was 1 (range 1-33), while the median tumor size was 3.6 cm (range 1.1-28). Of those, 94 (29 %) had postoperative complications, of which 6 % were graded as major (Dindo III-IV). The 90-days mortality was 2 %. The MELD, APRI, and CPT scores were not found to be statistically significant for complications, while combining BIL and CHE we defined four classes of risk. The association of BIL >1 mg/dl (>17.1 µmol/l) and CHE ≤ 5,900 U/l was the best to detect complications (OR = 4.45; P = 0.007).
This study shows that our selection criteria that count mainly on two commonly available, and inexpensive parameters, BIL and CHE, lead to identify patients potentially at risk of postoperative complications after hepatic resection for HCC.
NCT02056041 ( http://www.clinicaltrials.gov).
肝细胞癌(HCC)肝切除术的选择标准存在争议。我们提出了HCC安全肝切除术的标准,并将结果与使用最常见的HCC评分所获得的结果进行了比较。
从我们前瞻性维护的数据库中回顾了所有基于相同标准接受HCC肝切除术的患者。这些标准包括胆红素(BIL)、胆碱酯酶(CHE)、腹水、食管静脉曲张和残余肝体积。
共分析了336例患者。115例患者(33%)采用胸腹联合入路,但只有39例(12%)进行了大手术或扩大切除术。肿瘤中位数为1个(范围1 - 33个),而肿瘤中位数大小为3.6 cm(范围1.1 - 28 cm)。其中,94例(29%)有术后并发症,其中6%为严重并发症(Dindo III - IV级)。90天死亡率为2%。未发现终末期肝病模型(MELD)、天冬氨酸氨基转移酶与血小板比值指数(APRI)和Child - Pugh - Turcotte(CPT)评分对并发症有统计学意义,而将BIL和CHE结合起来我们定义了四类风险。BIL>1 mg/dl(>17.1 µmol/l)且CHE≤5900 U/l的联合指标对检测并发症的效果最佳(比值比[OR]=4.45;P = 0.007)。
本研究表明,我们主要基于两个常用且廉价的参数BIL和CHE的选择标准,能够识别出HCC肝切除术后可能有术后并发症风险的患者。
NCT02056041(http://www.clinicaltrials.gov)